Gilead Sciences, Inc. vs Merck & Company, Inc. — Stock Comparison
Gilead Sciences, Inc. (GILD) and Merck & Company, Inc. (MRK) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Merck & Company, Inc. narrowly edges Gilead Sciences, Inc. on Q·Score (6.3 vs 5.8 out of 10), led by Quality (4.9 vs 2.7) and Health (7 vs 5.5). Gilead Sciences, Inc. scores higher on Valuation, reflecting stronger P/E and price-target positioning. Analyst consensus targets imply greater upside for GILD (+7.7%) than for MRK (-3.1%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
76% of 29 covering analysts have a positive rating.
⚠ currently unprofitable (-11% margin).
71% of 28 covering analysts have a positive rating.
⚠ weak profitability metrics drag quality score.
Analyst Consensus
Fundamentals
Frequently Asked Questions
GILD vs MRK: which stock scores better overall?
Based on Q·Score, Merck & Company, Inc. (MRK) scores 6.3/10 versus Gilead Sciences, Inc. (GILD) at 5.8/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: GILD or MRK?
Gilead Sciences, Inc. (GILD) scores higher on Growth (7.1/10 vs 6.4/10). Gilead Sciences, Inc. reports revenue growth (10.2% YoY) while Merck & Company, Inc. reports (5.1% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is GILD or MRK more attractively valued?
Gilead Sciences, Inc. (GILD) scores higher on Valuation (7.3/10 vs 6.5/10). GILD trades at 14.8× P/E versus MRK at 16.0×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about GILD vs MRK?
There are 27 analysts covering GILD with a consensus price target of $157.41, and 26 analysts covering MRK with a consensus target of $147.77. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: GILD or MRK?
Merck & Company, Inc. (MRK) scores higher on Quality (4.9/10 vs 2.7/10). Net profit margin: GILD at -10.6%, MRK at 4.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: GILD or MRK?
Merck & Company, Inc. (MRK) scores higher on Financial Health (7/10 vs 5.5/10). Market beta: GILD at 0.34, MRK at 0.21. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of GILD and MRK?
Gilead Sciences, Inc. (GILD) has a market capitalisation of $181.2B, while Merck & Company, Inc. (MRK) has a market cap of $376.4B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do GILD or MRK pay dividends?
GILD pays a dividend yield of 2.24%, while MRK pays a dividend yield of 2.23%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →